| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 645 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | BLSM Blossomhill Therapeutics, Inc. Common Stock | Keyes Jason A72 | Chief Financial Officer | Buy | 700 | $16.00 | $11,200.00 | New | |
| Aug 10, 2026 | BLSM Blossomhill Therapeutics, Inc. Common Stock | Liptak Vincent Paul | General Counsel | Buy | 4,700 | $15.89 | $74,700.00 | +2.2% | |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. Common Stock | Chimovits Erez | Director, 10% Owner | Buy | 1,940,000 | $18.00 | $34,920,000.00 | +19.0% | |
| Aug 7, 2026 | PRTA Prothena Corporation Plc | Scully William P | 10% Owner | Buy | 37,500 | $8.62 | $323,220.00 | +4.5% | |
| Aug 7, 2026 | SYRE Spyre Therapeutics, Inc. | Albers Jeffrey W.65 | Director | Sell | 23,000 | $104.53 | $2,404,190.00 | -44.5% | |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. Common Stock | Orbimed Advisors LLC66 | Director, 10% Owner | Buy | 1,940,000 | $18.00 | $34,920,000.00 | +19.0% | |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. Common Stock | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | Buy | 3,600,000 | $18.00 | $64,800,000.00 | +19.8% | |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. | Garcia Marino | CEO And President | Sell | 166,000 | $108.11 | $17,945,451.37 | -12.6% | |
| Aug 7, 2026 | MNKD Mannkind Corporation | Binder Steven B.66 | Director | Sell | 39,051 | $4.06 | $158,547.06 | -4.7% | |
| Aug 6, 2026 | IRON Disc Medicine, Inc. | Khara Rahul45 | Chief Legal Officer | Sell | 5,000 | $80.00 | $400,000.00 | -8.7% | |
| Aug 6, 2026 | PTIX Protagenic Therapeutics, Inc. | Armen Garo H49 | Exec. Chair &Principal Off | Buy | 685 | $0.22 | $150.70 | +2.2% | |
| Aug 6, 2026 | AMGN Amgen Inc. | Miller Derek | SVP, Human Resources | Sell | 3,890 | $402.54 | $1,565,897.72 | -13.5% | |
| Aug 6, 2026 | AMGN Amgen Inc. | Grygiel Nancy A.55 | SVP &CCO | Sell | 2,970 | $402.16 | $1,194,415.50 | -16.8% | |
| Aug 6, 2026 | AXSM Axsome Therapeutics, Inc. | Tabuteau Herriot45 | Chief Executive Officer | Sell | 49,664 | $212.19 | $10,538,305.04 | -77.5% | |
| Aug 5, 2026 | PCVX Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Sell | 17,000 | $55.00 | $935,068.00 | -18.1% | |
| Aug 5, 2026 | APGE Apogee Therapeutics, Inc. | Dambkowski Carl47 | Chief Medical Officer | Sell | 5,500 | $134.17 | $737,935.00 | -3.2% | |
| Aug 5, 2026 | PTIX Protagenic Therapeutics, Inc. | Armen Garo H49 | Exec. Chair &Principal Off | Buy | 5,000 | $0.26 | $1,294.00 | +19.0% | |
| Aug 5, 2026 | TLSA Tiziana Life Sciences Ltd | Elrifi Ivor | Chief Executive Officer | Buy | 321,423 | $0.99 | $318,908.79 | +3.6% | |
| Aug 4, 2026 | NRIX Nurix Therapeutics, Inc. | Van Houte Hans60 | Chief Financial Officer | Sell | 4,761 | $24.36 | $115,989.47 | -5.4% | |
| Aug 4, 2026 | ELVN Enliven Therapeutics, Inc. | Derynck Mika K | Director | Sell | 158,795 | $60.21 | $9,561,586.85 | -100% | |
| Aug 3, 2026 | SYRE Spyre Therapeutics, Inc. | Burrows Scott L72 | Chief Financial Officer | Sell | 7,500 | $95.57 | $716,771.00 | -2.5% | |
| Aug 3, 2026 | CTRVP Hepion Pharmaceuticals, Inc. | Appajosyula Sireesh | Chief Operating Officer | Buy | 2,000,000 | $0.05 | $100,000.00 | +160.0% | |
| Aug 3, 2026 | MPLT Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | Sell | 22,082 | $12.54 | $276,908.28 | -9.8% | |
| Aug 3, 2026 | ARQT Arcutis Biotherapeutics, Inc. | Matsuda Masaru50 | See Remarks | Sell | 1,230 | $26.12 | $32,123.66 | -1.0% | |
| Aug 3, 2026 | CTRVP Hepion Pharmaceuticals, Inc. | Stetz Gary S. II | Director | Buy | 500,000 | $0.05 | $25,000.00 | New |